Synopsis
Medical Implications of Basic Research in Aging provides a sampling of the most important discoveries of the past several years relevant to aging research in the context of enhancing life- and healthspan. Have you ever wondered if there is anything that you can do to slow aging or prevent diseases associated with aging? Are you interested in enhancing your health based on the latest scientific discoveries? Are you a biohacker experimenting on your own body in an attempt to live longer? Assembled in this volume are a number of the commentaries that previously appeared in the scientific journal Rejuvenation Research. The presentations are clearly written and accessible to those with a general background in biology and medical science. An overview summarizes the articles for the educated layman. Thorough referencing provides an opportunity for further in-depth reading.
About the Author
Dr. Andrew Mendelsohn has been deeply interested in the biology of aging for many years. He founded the 501(c)(3) non-profit Regenerative Sciences Institute in 1994 to pursue research at the interface of aging, regeneration, and what is now called synthetic biology. In 1997, he co-authored one of the earliest papers in synthetic biology. He also serves as Director of Molecular Biology at the Panorama Research Institute, which seeks to develop state-of-the-art therapeutics and is a co-founder of Wintgen LLC which seeks to alter Wnt pathway regulation to cure macular degeneration. He serves as Director of Research at Regenerative Sciences Institute (http://www.regensci.org), which seeks to overcome aging by using synthetic and computational biology to engineer enhanced regeneration and rejuvenation. Development of appropriate dynamic computer simulations of aging biological systems is ongoing. At the heart of our approach is the creation and insertion of new biological programs into cells to augment pre-existing incomplete regeneration mechanisms. Dr. James Larrick is a biomedical entrepreneur with an international reputation in biotechnology [cytokines, therapeutic antibodies, molecular biology, pharmaceutical drug development] having written or co-authored eight books, over 250 papers/chapters and >forty patents in his twenty-five year career. He has served on the editorial board of six journals. Dr. Larrick’s work on therapeutic antibodies and other protein therapeutics has spanned the whole range of biopharmaceutical product development from target discovery, process science to clinical trials. Dr. Larrick received his MD and PhD. degrees from Duke University School of Medicine. He trained at Stanford and was then a founding scientist at Cetus Immune where he became Director of Research. In 1992, Dr. Larrick founded the non-profit Panorama Institute of Molecular Medicine, and Panorama Research Inc., a biotech incubator. Dr. Larrick’s team has discovered developed a diverse, and innovative portfolio of pharmaceutical molecules addressing major unmet needs in cancer, infectious, autoimmune, cardiovascular, neurological and metabolic diseases. PRI has incubated >20 life science companies,. including Kalobios, Absalus Inc. (now Teva Inc.), Galaxy Biotech, and TransTarget Inc. Dr. Larrick has been a member of angel groups and serves as a managing director and Chief Medical Officer of Velocity Pharmaceutical Development LLC in S. San Francisco.
"About this title" may belong to another edition of this title.
